Eli Lilly & Co. stock falls 2.61% amid poor market session

16 articles · Updated · MarketWatch · Apr 29

Shares closed at $851.21, nearly 25% below their January 8th 52-week high, with trading volume reaching 3.9 million.
Eli Lilly underperformed competitors Johnson & Johnson, Pfizer, and AbbVie, as the S&P 500 and Dow Jones also declined.
The broader market downturn contributed to the stock's drop, with Eli Lilly's trading volume exceeding its 50-day average by 1 million shares.

Eli Lilly's stock is falling despite strong forecasts. What does Wall Street see that others don't?

Will Eli Lilly's multi-billion dollar shopping spree shield it from the escalating weight-loss drug price war?

With a new 'king' of weight loss on the horizon, can any competitor catch up to Eli Lilly's pipeline?

Lilly's new drug causes 28.7% weight loss. What are the hidden health risks of such a powerful treatment?

Is Lilly's pivot to cancer and gene therapy a brilliant move or a costly distraction from its cash cow?

Cheaper weight-loss pills are here. Is this the end for expensive injections like Zepbound?